National Institute for Health and Care Excellence11d
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Healio11d
Findings allow for better risk assessment and personalized treatment for BRCA2 carriers
However, about once a year, companies that conduct BRCA genetic testing update variant classifications. “They send a new letter to that physician who ordered the test saying, ‘Here’s an upgrade.
ascopubs.org5d
Impact of BRCA status in patients with castrate-resistant prostate cancer undergoing abiraterone +/- stereotactic body radiotherapy: ARTO trial.
genomic, and radiographic prognostic features and novel risk classifiers compared to routinely available risk classifiers. Biochemical progression free survival (BPFS) results in the two trial arms ...